Acral lentiginous melanoma
MONDO:0003865A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin. It presents as a pigmented macular lesion with irregular borders. Morphologically, it consists of atypical spindled and dendritic melanocytes. The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.
Also known as: acral lentiginous malignant melanoma, acral lentiginous melanoma, acral lentiginous melanoma (disease), acral lentiginous melanoma, malignant, acral lentiginous melanoma, malignant (morphologic abnormality), ALM, acral lentiginous malignant melanoma of skin, acral melanoma
2783 clinical trials for this condition and its sub-types, 17 tagged with Acral lentiginous melanoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental drug dinaciclib tested in advanced melanoma patients
Disease control OngoingThis phase II trial is testing the drug dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. Researchers are looking at side effects and whether it helps patients live longer or slows tumor growth.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for brain lining cancer: immunotherapy injected directly into spinal fluid
Disease control OngoingThis early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could timing of immunotherapy boost melanoma survival?
Disease control OngoingThis phase II trial studies whether giving the immunotherapy drug pembrolizumab both before and after surgery is more effective than giving it only after surgery for patients with stage III-IV high-risk melanoma. About 313 participants will be randomly assigned to one of two trea…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC